TMDX Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: Approximately $190 million, up 21% year-over-year and 9% sequentially, marking the highest quarterly revenue in the company's history.

Transplant Product Revenue: $111 million, up 16% year-over-year and 3% sequentially.

Service Revenue: $79 million, up 29% year-over-year and 19% sequentially, driven by increased logistics utilization and pricing adjustments.

Adjusted Income from Operations: Approximately $25.8 million, representing an adjusted operating margin of 13.6%.

Cash Position: Ended the quarter with approximately $473 million in cash and cash equivalents.

Gross Margin: Total gross margin at 59.6%, with service margin improving to 35%.

2Strategic Updates and Business Highlights

New Initiatives: Launched donor and recipient clinical screening coordination services on July 1, 2026, aimed at streamlining transplant workflows.

Growth in Logistics: TransMedics Logistics revenue increased by 39% year-over-year, highlighting the effectiveness of vertical integration.

International Expansion: Closed a strategic investment in PAD Aviation to establish a European transplant logistics network, with plans to replicate the U.S. model.

Clinical Programs: Ongoing efforts with ENHANCE Part B and DENOVO trials, with expectations for significant contributions in late 2026 and 2027.

3Forward Guidance and Outlook

Revenue Guidance: Raised the lower end of full-year 2026 revenue guidance to $737 million to $757 million, representing 22% to 25% growth over 2025. This guidance excludes contributions from PAD Aviation and clinical programs ENHANCE Part B and DENOVO.

Operating Margin Outlook: Adjusted full-year operating margin guidance lowered to approximately 12.5% to 14%, reflecting increased investment in strategic growth initiatives.

4Challenges and Points of Concern

Stock Volatility: Management acknowledged stock volatility as investors weigh growth investments against near-term operating leverage.

Regulatory Delays: Concerns regarding the timing and approval of ENHANCE Part B and DENOVO trials, with potential impacts on revenue contributions.

Market Dynamics: Seasonal softness expected in Q3, with historical patterns suggesting lower transplant volumes during this period.

Integration Risks: Initial consolidation of PAD Aviation may be dilutive to gross and operating margins in the near term.

5Notable Q&A Insights

Service Revenue Growth: Management clarified that service revenue growth was driven by market share gains and operational efficiencies rather than an increase in dry runs.

Clinical Trial Updates: Management expressed confidence in completing ENHANCE Part A by year-end, with expectations for rapid adoption post-IDE approval for ENHANCE Part B.

International Reimbursement: Clarified that reimbursement discussions are ongoing, particularly in Italy, with potential for broader European expansion.

OPO Opportunities: Management remains cautious regarding potential OPO recertification impacts, emphasizing that growth strategies are not contingent on this outcome. Overall, TransMedics reported a strong quarter with record revenues and strategic advancements, while also navigating challenges related to regulatory timelines and market dynamics.